Arab Finance: Minapharm Pharmaceuticals recorded a standalone net profit of EGP 101.82 million in the first half (H1) of 2026, reversing a net loss of EGP 222.22 million a year earlier, according to financial statements submitted to the Egyptian Exchange (EGX).
Standalone sales rose to EGP 2.44 billion during the six months ending June 30, 2026, from EGP 1.92 billion in the corresponding period of 2025
During the second quarter alone, Minapharm posted a net profit of EGP 30.053 million, compared with EGP 25.29 million in the same quarter last year.
Sales for the three months ending June 30 reached EGP 1.31 billion, up from EGP 916.847 million.
Established in 1958, the company produces licensed and generic pharmaceuticals, vaccines, veterinary products, drug delivery systems, cosmetics, and skin care supplies. The company's expertise covers a broad spectrum of medicines, ranging from small molecules to extremely complex bioengineered proteins.
